Objective To evaluate the effect of Chinese medicine(CM)treatment on survival time and quality of life(QOL)in patients with small cell lung cancer(SCLC).Methods This was an exploratory and prospective clinical observa...Objective To evaluate the effect of Chinese medicine(CM)treatment on survival time and quality of life(QOL)in patients with small cell lung cancer(SCLC).Methods This was an exploratory and prospective clinical observation.Patients diagnosed with SCLC receiving CM treatment were included and followed up every 3 months.The primary outcome was overall survival(OS),and the secondary outcomes were progression-free survival(PFS)and QOL.Results A total of 136 patients including 65 limited-stage SCLC(LS-SCLC)patients and 71 extensive-stage SCLC(ES-SCLC)patients were analyzed.The median OS of ES-SCLC patients was 17.27 months,and the median OS of LS-SCLC was 40.07 months.The survival time was 16.27 months for SCLC patients with brain metastasis,9.83 months for liver metastasis,13.43 months for bone metastasis,and 18.13 months for lung metastasis.Advanced age,pleural fluid,liver and brain metastasis were risk factors,while longer CM treatment duration was a protective factor.QOL assessment indicated that after 6 months of CM treatment,scores increased in function domains and decreased in symptom domains.Conclusion CM treatment might help prolong OS of SCLC patients.Moreover,CM treatment brought the trend of symptom amelioration and QOL improvement.These results provide preliminary evidence for applying CM in SCLC multi-disciplinary treatment.展开更多
基金Surpported by National Natural Science Foundation of China(No.81673797)Beijing Municipal Natural Science Foundation(No.7182142)。
文摘Objective To evaluate the effect of Chinese medicine(CM)treatment on survival time and quality of life(QOL)in patients with small cell lung cancer(SCLC).Methods This was an exploratory and prospective clinical observation.Patients diagnosed with SCLC receiving CM treatment were included and followed up every 3 months.The primary outcome was overall survival(OS),and the secondary outcomes were progression-free survival(PFS)and QOL.Results A total of 136 patients including 65 limited-stage SCLC(LS-SCLC)patients and 71 extensive-stage SCLC(ES-SCLC)patients were analyzed.The median OS of ES-SCLC patients was 17.27 months,and the median OS of LS-SCLC was 40.07 months.The survival time was 16.27 months for SCLC patients with brain metastasis,9.83 months for liver metastasis,13.43 months for bone metastasis,and 18.13 months for lung metastasis.Advanced age,pleural fluid,liver and brain metastasis were risk factors,while longer CM treatment duration was a protective factor.QOL assessment indicated that after 6 months of CM treatment,scores increased in function domains and decreased in symptom domains.Conclusion CM treatment might help prolong OS of SCLC patients.Moreover,CM treatment brought the trend of symptom amelioration and QOL improvement.These results provide preliminary evidence for applying CM in SCLC multi-disciplinary treatment.
